Cash-poor Poxel SA is drawing nearer to a key decision about which of its two mid-stage non-alcoholic steatohepatitis candidates to move into Phase III, but positive top-line data reported on 30 August from a Phase II study of PXL065, a proprietary candidate derived from established diabetes drug pioglitazone, appeared to further de-risk at least one of its options.
Poxel, which reported cash on hand of €16.1m (about $16.8m) at the end of the second quarter, is focusing on NASH and rare metabolic diseases despite last year’s approval in Japan of Twymeeg (imeglimin), a first-in-class oxidative phosphorylation inhibitor for type 2 diabetes. (Also see "Stock Watch: Poxel Passes Go…But To Where?" - Scrip, 19 July, 2021.) The Lyon, France-based firm is leaving commercialization of Twymeeg to partner Sumitomo Dainippon Pharma Co., Ltd
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?